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Human  cDNA was mutagenized to duplicate six nat- 
urally occurring mutations in the gene for glucocere- 
brosidase. The mutant genes were expressed in NIH 
3T3 cells. The abnormal  human enzymes were purified 
by immunoaffinity chromatography and character- 
ized. The Asd7' + Ser mutant protein differed from 
normal enzyme in its inhibition by both conduritol B 
epoxide and glucosphingosine demonstrating that the 
370 mutant enzyme has an abnormal catalytic  site. In 
addition, the 370 mutant enzyme is less  activated by 
saposin C, but  more stimulated by phosphatidylserine 
than the wild type enzyme. The Arg4s3 + Cys mutant 
protein was normal with respect to conduritol B epox- 
ide and glucosphingosine inhibition, but was  less  acti- 
vated by  both saposin C and phosphatidylserine. The 
ArgI2'  Gln  mutant protein was  catalytically inac- 
tive. The + Pro, the pseudopattern, and the 
Pro4" + Arg mutants appear  to have reduced amounts 
of enzyme protein in cells. The studies demonstrated 
that mutations in the gene for glucocerebrosidase have 
different effects on the  catalytic  activity and stability 
of the enzyme. 
An inherited deficiency of glucocerebrosidase (EC 3.2.1.45) 
is  the  basis for the lysosomal storage of glucosylceramide in 
the heterogeneous group of disorders known collectively as 
Gaucher disease. Biochemical analyses of the enzyme from 
tissues  and cells  have  been  inconclusive, but have  suggested 
that  the clinical phenotype  is  related to  a  specific abnormality 
in  either  the  amount or activity of the  mutant enzyme (1-3). 
In a molecular approach to the study of the  mutations  re- 
sponsible for Gaucher disease, the  cDNA for  glucocerebrosi- 
dase  (GC)' was cloned ( 5 ) ,  and its sequence was determined 
(6, 7). Sequencing of mutant  GC  genes  has been carried  out, 
and  six  different  mutant alleles have  been  identified codon 
+ Pro (S), codon Am3?* + Ser (9), codon Arg'** + Gln 
(lo), codon Pro4'* + Arg (11), codon Arg463 "+ Cys (12), and 
a crossover  with the pseudogene (12,41). Only recently have 
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The abbreviations used are: GC, glucocerebrosidase; CBE, con- 
duritol B epoxide; 4MU-glc, 4-methylumbelliferyl-~-~-glucopyrano- 
side; PS,  phosphatidylserine;  TC, sodium taurocholate;  SDS, sodium 
dodecyl sulfate;  CRIM,  cross-reacting  materials; Bes, NJVbis(2-h~-  
droxyethyl)-2-aminoethane sulfonic acid. 
mutant  proteins derived from single  alleles  been  available  for 
study.  In  this  paper, we report  properties of mutant glucocer- 
ebrosidases  produced from six different alleles known to cause 
Gaucher disease. 
EXPERIMENTAL  PROCEDURES 
Materials 
Restriction endonuclease, reagents for DNA  sequencing, T4 DNA 
ligase, T4 DNA polymerase, and M13mpl8 were purchased from 
Bethesda Research Laboratories or New England Biolabs. Mutant 
Escherichia coli, strain  CJ 236, and  T4 gene 32 protein were obtained 
from Bio-Rad.  Cyanogen bromide-activated  Sepharose  4B was from 
Pharmacia  LKB Biotechnology  Inc. Cell culture  reagents  and G418 
were from Gibco Laboratories. [ W ~ ~ S I ~ A T P  and  [a-3ZP]dCTP were 
from Du  Pont-New  England Nuclear. Conduritol B epoxide (CBE) 
was obtained from Biomol Research Laboratories Inc. (Plymouth 
Meeting, PA). 4-Methylumbelliferyl-~-~-glucopyranoside (4MU-glc), 
phosphatidylserine (PS), sodium taurocholate  (TC),  and glucosphin- 
gosine were obtained from  Sigma. Other  reagents were of the highest 
grade available. 
Constructions 
Human  cDNA was mutagenized  using two  different methods. The 
first  method was site-directed mutagenesis (13). Briefly, the cDNA 
that encodes normal  human glucocerebrosidase was cloned into  the 
EcoRI  site of M13mp18 in  the 3' + 5' orientation for the Arg'" + 
Gln  mutation  and 5' + 3' orientation for the Pro4'' + Arg mutation. 
Double-stranded  cDNA was transformed  in  CJ 236(dut-,ung-) E. coli, 
to  make a uracil-containing single-stranded DNA. Following the 
isolation of the  uracil-containing  single-stranded DNA,  a  mutagenic 
primer was annealed,  and  the second strand was  synthesized with T4 
DNA polymerase and  T4 DNA ligase. The oligonucleotides  used to 
modify cDNA were 5'-ACATCATCCAGGTACCCAT-3' for the 
Arg"" + Gln  mutation  and 5'-TAGAACATGCGCTGTTTGT-3' for 
the  Pro4" + Arg mutation.  These oligonucleotides were synthesized 
on an Applied  Biosystem  Model 380B DNA Synthesizer  and purified 
using  a20%  polyacrylamide/urea  sequencing gel. The double- 
stranded  phage  DNA was transformed  in  JM107 (ung'). In  this  step, 
the uracil containing  strand  (containing  normal cDNA)  was inacti- 
vated,  and only the mutagenized cDNA  strand was grown. Twelve 
plaques were picked at random  and sequenced  by the dideoxynucle- 
otide chain termination method to confirm that only the mutant 
cDNA was present  (14).  The  other  method used to define and  con- 
struct  mutant  cDNA for GC in expression  vectors  employed  cDNA 
amplified by the polymerase chain reaction. The details of these 
procedures have  been reported  recently  (12). Briefly, total RNA was 
extracted from Gaucher disease  fibroblasts, and  the  complementary 
DNA was synthesized by avian myeloblastosis  virus  reverse transcrip- 
tase. The cDNA was amplified by the polymerase chain reaction. 
Amplified cDNA was ligated into M13mp18 and sequenced (14). 
Mutant  cDNA  containing  the Arg463 + Cys mutation was cut  with 
NsiIIBarnHI,  and a small  fragment which contained  the 463 mutation 
was isolated  from low melting agarose. This  NsiIIBamHI  fragment 
was cloned  into  the  NsiIIBarnHI  site of normal cDNA. The  mutant 
cDNA containing the -f Ser mutation was cut with ScaIINsiI, 
and a small  fragment was purified  which contained  the 370 mutation. 
This  fragment was cloned into  the  ScaI/NsiI  site of normal cDNA. 
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For the 444 mutation and the "pseudopattern" mutation, mutant 
cDNA containing the desired mutation was cut with ~ s t I I / B a m H I ,  
The fragment was purified and cloned into  the Ms~II/BamHI site of 
normal cDNA. These mutant cDNAs were confirmed to have the 
desired mutation by sequencing. The pseudopattern mutation con- 
tains single base substitutions  in codons 444,456, and 460 in exon 10 
and is probably the result of a gene conversion (12, 15). 
Transfection of NIH  3T3 Cells 
Mutant  and normal cDNA  were ligated into the EcoRI site of the 
pCDE vector. Transfection was carried out by the method of Chen 
and Okayama (16). N I H  3T3 cells were maintained in Dulbecco's 
modified Eagle's medium (high glucose)/lO% fetal calf serum. For 
transfection, 5 X lo5 cells were plated in 100-mm dishes and incubated 
overnight at 37 "C under 5% CO,. Then 20 pg of DNA (construct: 
pSVsNeo, 2:l molecular ratio) was  mixed with 0.25 M CaC12 and 0.5 
mi of 2 X BBS (50 mM) Bes (pH 6.95), 280 mM NaCl, 1.5 mM 
Na2HP0,).  The mixture was incubated for 10 min at  room tempera- 
ture. Calcium phosphate-DNA solution was added to cells in a drop- 
wise manner. The cells were incubated at 35 "C under 3%  CO, 
overnight. The next day, cells were washed with medium four times 
and incubated overnight a t  37  "C under 5% COz. After 24 h, the cells 
were split at l:lO, 1:5, and 1:3 and incubated for another 24  h. Then, 
G418 was added to culture medium at a  final concentration of 400 
pg/ml to select stable transfectants. After about 3 weeks, stable 
transfectants were picked and grown up to 5-20 confluent 150-mm 
dishes. 
Immunoaffinity Purification of Normal and Mutant 
Glucocerebrosidase 
Purification of the enzyme was carried out by the method of Aerts 
et al. (17). This method is specific of human glucocerebrosidase (18). 
Briefly, cells were harvested with trypsin-EDTA and washed with 
phosphate-buffered saline two times. Then cells were sonicated 10 s 
X 2 (40 watts/s) in 4 volumes of 50 mM potassium phosphate buffer 
(pH 6.5), 0.25% Triton X-100, and centrifuged at 10,OOO X g for 30 
min at 4 "C. The  supernatant was incubated overnight with 50 pi of 
cyanogen bromide-activated Sepharose 4B coupled to monoclonal 
antibody (8E4). The affinity resin was prepared according to the 
manufacturer's instructions. The monoclonal antibody (8E4) is spe- 
cific for human glucocerehrosidase and does not react with mouse 
glucocerebrosidase (18). After binding of the enzyme, the resin was 
washed  successively  with 0.1 M citrate  phosphate buffer (pH 6.0), 0.5 
M NaC1, 30% ethylene glycol in 0.1 M citrate phosphate buffer (pH 
6.O), 1% Triton X-100 in 0.01/0.02 M citrate phosphate buffer (pH 
5.4),  and 50% ethylene glycol in 0.1 M citrate phosphate buffer (pH 
6.0). The enzyme was eluted with 90% ethylene glycol in 0.1 M citrate 
phosphate buffer (pH 6.0). After dilution of the solution to 30% 
ethylene glycol, the immunoaffinity purification was repeated. 
Determination of Km Values for 4MU-glc 
Enzymtic activity of glucocerehrosidase was determined using 
4MU-glc as a substrate (17). For K,,, studies, the reaction mixture 
(200 pl) contained various concentrations of 4MU-glc (0.1-7.5  mM), 
0.1 M citrate  phosphate buffer (pH 5.4), 3.5 mM TC, 2.1 mM Triton 
X-lOO,0.1% bovine serum albumin, and a constant amount of enzyme 
activity. The reaction was incubated at 37 "C for 30 min and termi- 
nated by adding 3.8  ml  of  0.17 M glycine carbonate buffer (pH 10.4). 
Enzyme activities were expressed as nanomoles of substrate cleaved 
per h (nmol/h).  The amount of enzyme  was adjusted so that less than 
5% of t,he substrate was  hydrolyzed. K, values were determined from 
Lineweaver-Burk plots. 
Inhibition of Glucocerebrosidase  by  Glucosphingosine  and CBE 
For the glucosphingosine inhibition studies, the activities of normal 
and mutant enzyme in the incubation were equalized by diluting the 
enzyme extract with 0.1 M citrate phosphate buffer (pH 5.4), 0.1% 
bovine serum albumin. Glucosphingosine was dissolved in chloro- 
form:methanol {2:1, v/v), and  the  solvent^ was evaporated under a 
nit.rogen stream. Dried glucosphingosine was weighed and dissolved 
in 0.1 M citrate phosphate buffer (pH 5.4). The solution was sonicated 
briefly to disperse the lipid homogenously. The reaction mixture (200 
*I) contained 7.5 mM 4MU-glc, 0.1 M citrate phosphate buffer (pH 
5.4), 3.5 mM TC, 2.1 mM Triton X-100, 0.1% bovine serum albumin/ 
glucosphingosine (0-300 p ~ ) ,  and a constant. amount of enzyme 
activity. The incubation was  for  30 min at 37 "C and was terminated 
by adding 3.8 mi of 0.17 M glycine carbonate buffer (pH 10.4). Kt 
values were determined from Dixon plots. For CBE inhibition studies, 
the inhibitor was dissolved in water, and the required amounts (0- 
300 pM) were added to  the reaction mixture. ZSc values (concentration 
of CBE required to achieve 50% inhibition of enzyme activity) were 
determined from semilog plots of the activities. 
Activation of Glucocerebrosidase  by Synthetic Saposin. C and PS 
Saposin C was chemically synthesized using peptidylglycine a- 
amidating monooxygenase resins and  an automated solid phase pro- 
tocol based on the principles outlined by Merrified (19) on an Applied 
Biosystems model 430 peptide synthesizer. The sequence of the 82- 
amino acid peptide was as described by O'Brien et al. (20). This 
chemically synthesized saposin C, after refolding, has kinetic prop- 
erties nearly identical with naturally occurring saposin C. The details 
of the synthesis, folding, and kinetics of saposin C activation will  be 
described elsewhere? The reaction mixture (200 gl) contained 5 mM 
4MU-glc, 0.2 hi sodium acetate buffer (pH 5.0), 2.1 mM Triton X- 
100, 0.1% bovine serum albumin, varying concentrations of saposin 
C (0-20 pM), and a constant amount of enzyme activity. The reaction 
was incubated for 30 min at  37 "C and terminated by the addition of 
glycine buffer. For PS stimulation studies, PS was  dissolved in 
ch1oroform:methanol  (2:1, v/v). A small aliquot of this solution was 
removed, and the solvent was evaporated under a nitrogen stream. 
The weight of dried PS was measured and dissolved in distilled water 
at a final concentration at 1 pg/pl, The solution was sonicated briefly 
to disperse the lipid homogeneously. Varying amounts of PS (0-80 
pg) were added to  the reaction mixture described above. 
Heat Stability 
The normal and  mutant enzymes were diluted with 0.1 M citrate 
phosphate buffer (pH 5.4) and 0.1% bovine serum albumin to equalize 
the enzyme activity and  total protein concent.ration in all samples. 
The enzyme solution was placed at  50 "C, and enzyme activity was 
assayed in samples withdrawn at  0,2,5,30,  and 60 min. 
Gel Analyses 
Western Blot-NIH 3T3 cells transformed by the human genes 
were harvested with trypsin-EDTA and washed  twice with phosphate- 
buffered saline. The cell pellets were suspended in 50 mM potassium 
phosphate buffer (pH 6.5), 0.25% Triton X-100 and sonicated twice 
for 10 s on  ice  (40 watts/s). The cell homogenate was spun at 14,000 
X g for 5 min in a Microfuge. An aliquot of the sample was electro- 
phoresed in 7.5% SDS-polyacrylamide gel. The protein in the gel  was 
electroblotted onto nitrocellulose membrane at 100 V for 1 h. The 
nitrocellulose membrane was reacted with 8E4, and then alkaline 
phosphatase-conjugated goat anti-mouse IgG was reacted as a second 
antibody. The alkaline phosphatase reaction was carried out using 
nitroblue tetrazolium and 5-bromo-4-ch~oro-3-indolylphosphate to 
visualize cross-reacting materials (CRIM). 
N o r ~ ~ r n  Blot-Analyses  were carried out by a  standard method 
as described (22). Briefly, total RNA was extracted from the various 
transfected cells. Equal amounts of total RNA  were applied to a 1.2% 
agarose/formaldehyde gel and electrophoresed. Then,  the RNA was 
blotted onto nitrocellulose membrane and hybridized overnight at 
42 "C in 50% formamide, 5 X SSC, 1 X Denhardt's solution, 50 mM 
sodium phosphate buffer (pH 6.5), 0.1% SDS, 10% dextran sulfate, 
and 250 pg/ml salmon sperm DNA containing [a-"PIdCTP-labeled 
human GC cDNA (5).  The membranes were  washed with 2.5 X SSC, 
0.1% SDS for 4 X 10 min at room temperature and 0.3 X SSC, 0.1% 
SDS at 55 "C for 20 min. The amount of total RNA (10 gg) applied 
to each lane was equalized spectrophotometrically. The bands were 
visualized by autoradiography. 
Protein Concentration ~ e t e r m i ~ t i o n  
The protein concentration was determined using the Quantigold 
kit obtained from Diversified Biotech (Newton Center, MA). Bovine 
serum albumin was used as  the standard. 
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RESULTS 
The specific activity of GC  in  crude  extracts of 3T3 cells 
transformed by either  normal  or  mutant  human GC genes is 
shown in Fig. 1. The  amount of additional  activity above the 
endogenous 3T3 activity is that GC activity derived  from the 
human gene. It  can be seen  in Fig. 1 that  transformation of 
cells with the wild type GC gene results in the greatest 
increment of activity in the homogenates with  the 463 GC 
having the largest  activity among  the cells transformed with 
mutant GC alleles. 
Western  and  Northern  blots were carried  out to  estimate 
the relative amount of RNA and  protein produced  from  each 
mutant allele  compared to  that produced  by  a normal cDNA. 
Fig. 2 shows the  Western  blot of crude  extracts of 3T3 cells 
transformed by normal  or  mutant  human GC genes. Fig. 3 
shows the  Northern  blot of total  RNA from the  same  trans- 
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FIG. 1. The specific activity of glucocerebrosidase from 
various transfected cells  was determined using 4MU-glc as 
substrate. The reaction mixture  contained 7.5 mM 4MU-glc, 0.1 M 
citrate  phosphate buffer (pH 5.4), 3.5 mM TC, 2.1 mM Triton X-100, 
and cell extract. Enzyme  activity is expressed as  nanomoles/h/mg of 
protein.  The relative amounts of CRIM  and  RNA  are also shown. 
These values are expressed as percent of the  CRIM  and  RNA  in cells 
carrying normal GC cDNA. 
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FIG. 2. Western blot of crude cell extracts of cells trans- 
formed with normal and mutant  human cDNA. 100 pg of protein 
from the  crude  extracts of cells transformed with the six different 
human cDNAs  was  electrophoresed in 7.5% SDS-polyacrylamide gel 
and electroblotted onto a  nitrocellulose  membrane. Immunostaining 
was  carried out using 8E4 as described under  "Experimental  Proce- 
dures." A and B are  separate  experiments. A, NIH  3T3 cells trans- 
fected with: lane I, normal  cDNA; lane 2, Arg'":' -* Cys  cDNA; lane 
3, pseudopattern cDNA; lane 4, Leu444 -* Pro cDNA; lane 5, Asn"" 
+ Ser cDNA, B, NIH 3T3 cells transfected with: lane I, normal 
cDNA; lane 2, Arg"" + Gln cDNA; lane 3, Pro41s + Arg  cDNA; lane 
4, no cDNA (cell extract of NIH  3T3). 
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FIG. 3. Northern blots of various transfected cells. Total 
RNA from transfected cells was isolated, and 10 pg was electropho- 
resed in  each  lane of a 1.2% agarose  formaldehyde gel. The  fraction- 
ated RNA was blotted onto nitrocellulose  membrane and hybridized 
with a radiolabeled full length cDNA probe from GC. A and H are 
separate  experiments. A, RNA from NIH 3T3 cells transfected with: 
lane I, normal  cDNA; lane 2, Arg'"' --.f Cys cDNA; lane 3, pseudopat- 
tern cDNA; lane 4, + Pro cDNA; lane 5 ,  Asn""' + Ser cDNA. 
€8, RNA from NIH  3T3 cells transfected with lane I ,  normal cDNA; 
lane 2, Arg"" --.f Glu  cDNA; lane 3, Pro4I4 -* Arg cDNA; lane 4, no 
cDNA (RNA from NIH 3T3); lane 5, RNA from normal human 
fibroblast. 
formed cells probed  with  a 1700-base pair cDNA for human 
GC (5). Panels A and B in each figure represent separate 
experiments,  each with their own controls. These gels show 
that  the  amount of cross-reactive protein produced from the 
463 GC  mutant gene is equal to  that produced from the wild 
type cDNA (Fig. 2A, lane 2).  The  amount of RNA produced 
from the 463 GC allele is  about  equal  to  that from the wild 
type cDNA. In  contrast,  little  or  no  CRIM for the 444 GC 
and pseudo-GC proteins could be identified (Fig. 2 A ,  lunes 3 
and 4 ) .  The  amount of RNA in cells expressing these  muta- 
tions  is slightly greater  than  normal (Fig. 3A, lunes 3 and 4) .  
The  results suggest that  the enzyme protein resulting from 
these two mutant  GC alleles is unstable.  Although the possi- 
bility exists  that  8E4 does not react with 444 GC  and pseudo- 
GC, this conclusion is not  consistent with previously reported 
CRIM  and pulse-labeling studies of Type 2 and  Type 3 cells 
which carry  the 444 and/or  pseudopattern  mutations (8, 12, 
21,28,33,  34,40).  Independently,  another group has come to 
the  same conclusion, i.e. that 444 GC is an  unstable protein 
(4). 
Cells transformed with the 370 GC mutant allele have an 
identical  amount of CRIM  as compared to  the normal cDNA 
(Fig. 2A, lune 5 ) ,  and  the  amount of RNA is approximately 
equal  to  normal (Fig. 3A, lane 5 ) .  These  results suggested that 
the 370 GC is  stable  but catalytically  altered. The 120 GC has 
-50% CRIM of normal GC (Fig. 2B, lunes 1 and 2) .  The 
amount of RNA  for this  mutant is slightly lower than  normal 
(-80%) (Fig. 3B, lunes 1 and 2).  Taking into account the 
amount of RNA, the  amount of 120 GC cells could be esti- 
mated to be 60-70% of normal GC. It  is more likely that 
reduced catalytic activity, rather  than a  decrease  in enzyme 
protein, is responsible for the decreased amount of enzymatic 
activity in cells expressing this  mutation.  The 415 GC has 
only -5% CRIM of normal  GC (Fig. 2B, lune 3 ) .  Northern 
blots show that  the RNA for the 415 GC: is lower than normal 
(-60%) (Fig. 3B, lune 3 ) .  Taking  these  data  into account, the 
415 GC is probably an  unstable protein. These  studies of the 
Western  and  Northern  blots suggest that 370 GC and 463 GC 
are as stable as normal GC. The 120 GC is somewhat less 
stable  than normal, but  that  this  cannot be causative of the 
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low activity ( 4 0 % )  of GC in  transfected cells. 
Immunoaffinity  purification of GC using the monoclonal 
antibody 8E4 results in a homogeneous preparation of the 
enzyme  from human sources (17, 29).' This monoclonal an- 
tibody (8E4), which recognizes the N terminus of human GC, 
does not  react with  mouse GC either  in solution or  on  Western 
blot  analyses (Fig. 2). The  immunoaffinity  procedure readily 
separates  the  human  activity expressed in mouse  cells from 
the endogenous mouse enzyme (18). In  the  current  studies, 
NIH 3T3 cells served as a control of the immunoaffinity 
separation of human glucocerebrosidase  from the mouse ac- 
tivity. Assays of extracts of nontransfected cells eluted  from 
the  8E4 resin  revealed that  no  measurable  GC  activity  could 
be recovered. Only those NIH 3T3 cells transfected with 
normal  and  mutant  human  cDNA  produced  GC  that  could  be 
harvested by the immunoaffinity procedure. These results 
demonstrate  that only human  proteins were isolated  using  the 
immunoaffinity method. 
Further,  this  method  is useful  for the isolation of human 
glucocerebrosidases from the expression  system. Proteins 
from both  the wild type  and  mutant genes  could be isolated. 
The properties of the enzyme expressed from the normal 
cDNA were essentially identical  with  the homogenous  enzyme 
prepared from human  placenta  (Table I and Figs. 4 through 
7). The degree of purification of normal, + Ser mutant 
(370 GC),  and Arg463 + Cys mutant (463 GC) enzyme was 
approximately  the  same being  between 2000- and 4000-fold 
consistently. The  method  resulted  in  obtaining  enough of two 
mutant GCs to  permit  further  characterization of their  en- 
zymologic properties (see below). The Arg'" + Gln (120 GC) 
protein expressed in 3T3 cells cross-reacted  with  8E4 (Fig. 2). 
It could be recovered from  the  immunoaffinity  resin,  has  the 
same molecular weight as normal GC (60,000), but  had  no 
enzymatic activity. The Pro415 + Arg (415 GC)  reacts  with 
8E4  and  has  the  same olecular  weight as the  normal enzyme 
(Fig. 2). We have previously shown that a cell line (0877) 
carrying  the 444 and  pseudopattern  mutations  (see Ref. 12) 
produces  a protein  that  cross-reacts  with  8E4 (3, 28).' How- 
ever, the signal is consistently weaker. On gels overloaded 
with protein, these two mutant glucocerebrosidases can be 
shown to have a molecular weight identical with that of 
normal  GC  (data  not shown). In  standard  Western  blots of 
extracts of 3T3 cells  expressing these two proteins,  the  en- 
zyme proteins were at the  limit of detection (Fig. 2). These 
studies demonstrate that the molecular weight of all the 
mutant  proteins does not differ from  the wild type.  Sufficient 
amounts of 415 GC, 444 GC, and pseudo-GC were not avail- 
able  to  further  characterize  these  mutant  proteins.  The 463 
GC and 370 GC were studied  further,  and  these  results  are 
described below. 
Table I shows the K,,, values of 4MU-glc, Ki values for 
glucosphingosine  specific activities,  and molecular  weights of 
GC derived from normal and mutant cDNA compared to 
purified  human  placental GC. The  Km and Ki values of GC 
derived from  normal  cDNA  are  almost  identical  with  those of 
purified human  placental enzyme (23, 24). The Ki value of 
463 GC is  the  same  as  that of normal GC. The 370 GC has a 
Kc value  15-fold  higher than  that of normal  and  the 463 GC 
(150 pM versus 10 pM). Glucosphingosine at 200 pM nearly 
completely inhibits  the  activity of normal  and 463 GC, but 
only partially  inhibits  the 370 GC. The specific activities of 
normal  and  mutant GCs are also  shown. The specific activity 
of GC derived from normal cDNA is the same as that of 
purified human  placental enzyme. The specific activity of  370 
GC and 463 GC are 5% and 40%  of normal GC, respectively. 
The inhibition curve for CBE is shown in Fig. 4. CBE 
putatively  reacts  in  the  catalytic  site of  GC to  form a  covalent 
bond  with  aspartate residues  (25). The 370 GC required much 
more CBE  to  inhibit  the enzyme  activity. From  the semilog 
plot of the  inhibition curve  for CBE, Ib0 values of the 370 GC 
were 7.8-fold higher than  that of normal GC and  the 463 GC 
(585 p~ versus 75 p ~ ) .  This  result  demonstrates  that  the 370 
GC has a catalytic site, which while less efficient, requires 
more CBE  to  inhibit it. 
Fig. 5 shows the  activation profile of normal  and  mutant 
GC by saposin C. The 370 GC and 463 GC were both less 
TABLE I 
Properties of wild type and  mutant glucocerebrosidase cDNA expressed in NIH-3T3 cells 
Enzymatic  properties of normal  and  mutant glucocerebrosidases K, values for 4MU-glc were determined by 
Lineweaver-Burk plots of enzyme activities using different concentrations of 4MU-glc. The reaction mixture 
contained  the  required  amounts of 4MU-glc (0.1-7.5 mM) 0.1 M citrate  phosphate buffer (pH 5.4), 3.5 mM TC, 2.1 
mM Triton X-100, 0.1% bovine serum albumin, and a constant amount of enzyme activity. Ki values for 
glucosphingosine were determined  from  Dixon  plots of enzyme activities  using  concentrations of glucosphingosine 
(0-300 PM) and a constant amount of enzyme activity. K,,, and K, for purified human placental enzyme were 
obtained  in  three  separate  experiments. Assays were performed  in duplicate. Separate  experiments were performed 
for the enzymes  purified  from the expression  system. For  the  measurement of K,, seven concentrations of 4MU- 
glc were used. For  the  measurement of Ki, six different  concentrations of glucosphingosine were used at three 
different  concentrations of substrate. The assays were performed  in  duplicate. The specific activities  are expressed 
as nanomoles of 4MU-glc hydrolyzed per h per mg of protein  (nmol/h/mg). Molecular  weights were determined 
from Western  blots  (see Fig. 2). 
w ~ ~ ' ~ ~ ~ 3 ,  Specific  activity K,  K, Activation  Maximum  sti - Heat by saposin C ulation  by PS stability 
Human  placental gluco- 
cerebrosidase 















nrnoljhjmg mM WM -fold -fold 
1.9 & 0.1 X lo6" 2.7 +- 0.2b 7.5 +- 1.5b 4 8 Stable 
2.2 x lo6 4.0 10 3 8 Stable 
8.3 x 10' 4.0 10 1.5 4 Unstable 





Mean 5 S.D. of three  different  preparations. 
* Mean +- S.D. of three  different  experiments. 
ND,  not  determined. 
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FIG. 4. Inhibition of GC by CBE. Normal and mutant GC 
purified from the expression system were inhibited by various con- 
centrations of CBE. Responses were compared to purified placental 
GC. The reaction mixture contained 7.5 mM 4MU-glc, 0.1 M citrate 
phosphate buffer (pH 5.4),  3.5 mM TC, 2.1 mM Triton X-100, 0.1% 
bovine serum albumin, the required amount of CBE (0-300 wM), and 
a constant amount of enzyme activity. The amount of enzyme activity 
in the assay was equalized between samples. Is0 values were deter- 
mined as  the concentration of CBE required to achieve 50% inhibition 
of enzyme activity. A-A, purified placental GC; o"-o, normal 
GC; U, 370  GC; X-X, 463  GC. 
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FtG. 5. Stimulation of normal and mutant GC by synthetic 
saposin C. Normal and mutant GC purified from the expression 
system were stimulated by various concentrations of saposin C  and 
compared to the effects of saposin C on homogeneous placental 
enzyme. The reaction mixture contained 5 mM 4MU-glc, 0.2 M sodium 
acetate buffer (pH 5.0), 2.1 mM Triton X-100, 0.1% bovine serum 
albumin, required concentration of saposin C (0-20 MM), and a 
constant amount of enzyme activity. The amount of normal and 
mutant GC added to the reaction was equalized after  determining  the 
activity of each in an assay without added saposin C. Each point is 
an average of duplicate assays. The experiments on purified placental 
GC were repeated at least three times. Separate experiments were 
performed for each enzyme purified from the expression system. 
A-A, pure placental GC; M, normal GC; c"., 370 GC; 
X-X. 463  GC. 
activated  by  saposin C compared to normal  GC.  Normal  GC 
was  activated  by  saposin C %fold,  but  the  463 GC was 
activated only 1.5-fold by up to a 20 pM concentration of 
saposin C. T h e  370  mutant  GC  was  activated  only  1.3-fold  by 
saposin C. These results show that both of these mutant  
proteins  are  less well activated in vitro by  saposin C. 
The activation  profile of normal and mutant  GC by PS is 
shown  in  Fig. 6. Normal  GC  is  stimulated  by PS 8-fold, a n d  
t h e  463 GC was stimulated 4-fold. These results show that 
these  two  mutant  GCs  have  very  different  catalytic  properties 
with  respect  to  stimulation  by  the  acidic  lipid PS. T h e  data 
also  show  that in  vitro PS is  less  stimulatory  for  the  370  GC 
at higher concentrations under the conditions used. Other 
lipids  have  been  shown  to  have a range of stimulatory  con- 
centrations  which  when  exceeded are less  effective  in  stimu- 
lating  the  activity of pure  or  crude  preparations of GC (26, 
27, 38). The reasons  for  this  effect  are not understood,  but 
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FIG. 6. Stimulation of normal  and  mutant GC by PS. Normal 
and mutant GC were stimulated by various concentrations of PS. 
The reaction mixture was as previously described under "Experimen- 
tal Procedures." The range of PS concentrations was 0 to 80 pg. The 
amount of normal and  mutant enzyme in the reaction was equalized 
after determining its activity without PS. The  data presented are  the 
average of duplicate assays. A-A, pure placental GC; W, 
normal GC; U, 370 GC; X-X, 463  GC. 
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FIG. 7. Heat stability of normal  and  mutant GC. The activity 
of normal and mutant GC in separate tubes was equalized by adjusting 
the amount of enzyme added to 0.1 M citrate phosphate buffer (pH 
5.4). The total protein concentration was made equal in each sample 
by adding an appropriate  amount of 0.1% bovine serum albumin. The 
enzyme was placed at 50 "C, and enzyme activity was assayed at 0,2, 
5, 30, and 60 min. A-A, pure placental GC; M, normal GC; 
M, 370 GC; X-X, 463  GC. 
probably  relate to the interaction and optimal  proportions of 
the multiple components involved in the reaction. In other 
experiments on extracts of cells  from  type 1 Gaucher  cases, 
the  combination of saposin C and PS i n  vitro results  in  activity 
that approximates normal enzyme activity (42). Since cells 
from Type 1 cases  have the highest  probability of carrying a 
370  mutation (8, 9, 33, 34), the  effect of PS on  the 370 GC  is 
most  likely to be  responsible  for  these  observations. 
Fig.  7 is  a plot  of the heat stability of normal and mutant  
GC. The  normal and the 370 GC  are  stable  for 1 h at 50 "C, 
but  the enzyme  activity of the  463  GC  was  decreased  to  37% 
of the  initial  activity.  This  result  clearly  demonstrates  that 
different  mutant  glucocerebrosidases  have  different  heat  sta- 
bilities. 
DISCUSSION 
Recently,  several  mutations  in  the  gene  for  glucocerebrosi- 
dase have been described (8-12). However, the relationship 
between genotype and phenotype remains obscure. For ex- 
ample,  the  Leu444 + Pro mutation  is  found  predominantly  in 
severe cases of Gaucher disease (Types 2 and 3), but to a 
lesser  extent  occurs  in  clinically  mild  cases  (Type 1 Gaucher 
disease) (8, 9, 33, 34). In addition,  cells  derived  from  Gaucher 
patients  often  have been shown to carry  two  different  mutant 
alleles,  so-called  compound  heterozygotes (8-12, 30, 34). T h e  
enzyme isolated from patient materials therefore is often 
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composed of two different  mutant  proteins.  In  the  past, bio- 
chemical studies were carried  out  on residual  glucocerebrosi- 
dase activities  from Gaucher  patients using crude  or  partially 
purified  enzyme preparations. The shortcomings of biochem- 
ical studies in assigning a property characteristic of any 
phenotype  are explainable given the molecular  genetics cited 
above. The presence of more than one enzyme protein in 
samples no doubt is the reason for different biochemical 
results  obtained  in  different  laboratories  (1,31).  In  this  study, 
we characterized the purified normal  and  mutant GC enzymes 
derived from single alleles to define the properties of the 
mutant proteins. We  can conclude that  different  mutations 
result in mutant enzymes with different properties. This 
approach helps clarify previous studies of the enzyme and 
provides direct evidence for the differences in  the  properties 
of glucocerebrosidase that have been observed in patient 
material. For  example,  glucocerebrosidase studied  in Ashke- 
nazi Jewish  patients  with  Type 1 Gaucher disease has  been 
reported  to be either  catalytically  altered or unstable or both 
(1, 2, 25, 26, 31, 32, 35).’ Several mutations occur in the 
Jewish  population heteroallelically most  often  in  combination 
with  the 370 mutation (8, 9, 11, 30, 33, 34). One of these  is 
the codon 444 mutation. Our data show that the 444 GC 
protein  is probably unstable which is  consistent  with  earlier 
CRIM, pulse-labeling, and immunocytochemical data (2, 3, 
21,28,40).  Thus,  reports  demonstrating  alteration of different 
properties of GC in  the  same  phenotype  are  supported by our 
data, i.e. GC in  Type 1 patients may be catalytically ineffi- 
cient,  unstable, or both,  depending  on  the  mutations  present. 
The activation of GC by saposins (heat-stable factors or 
sphingolipid-activating factors) and acidic lipids has been 
reported  to be altered  in  some  studies of GC, but  not  others 
(31).  Our  data show that  saposin C  poorly stimulates  the 370 
GC and 463 GC mutant protein as compared to normal. 
However, the 370 GC is stimulated  to a greater  extent by PS 
than  either  the  normal or 463 GC enzyme.  Moreover, Type 1 
cells which probably carry the 370 codon mutation can be 
stimulated  to  near  normal  activity in  vitro by the  combination 
of PS and saposins.* The  studies  reported  in  this  paper show 
that  the Ki for glucosphingosine and 150 for CBE  are  identical 
between 463 GC and  normal GC indicating  that  the  active 
sites of the  proteins  are very similar.  In  light of the specific 
activity of 463 GC being about 40% of normal,  these obser- 
vations  and conclusions are  not  too  surprising. However,  463 
GC is poorly stimulated by saposin C and PS, implying that 
the  activity of GC in the lysosome may depend on  its  ability 
to  be activated by in situ saposins and endogenous lipids. 
Indeed, two examples of saposin C deficiency as a cause of 
Gaucher disease  have  been reported  (36,37).  The 463 GC may 
be the first example of a refractory response to  saposin 
stimulation  as a cause for Gaucher disease. The  interaction 
of saposin and GC is being studied  further  in  our  laboratory. 
Two proteins  and  other cellular constituents  are  important 
to  the activity of glucocerebrosidase. We  have shown  in this 
report  that  mutations  in  the glucocerebrosidase gene can  alter 
one or more components of the  enzymatic  catalysis of gluco- 
sylceramide. In  this regard, Morimoto et al. (38)  proposed a 
four-binding site model of glucocerebrosidase: one for the 
carbohydrate of substrate, one for the aglycon, one for the 
lipid, and one for the saposins. Other investigators have 
reported that PS and glucosphingosine bind to the same 
domain (39). However, in our study,  the 463 mutant enzyme 
had a normal response to glucosphingosine and  an abnormal 
response to PS. This suggests that PS and glucosphingosine 
may bind  to  different  domains,  and  that  the  number of sites 
interacting in the catalysis may be more than previously 
predicted. 
Finally,  previous studies of thermostability of mutant glu- 
cocerebrosidases yielded different  results  in  material  obtained 
from  patients (26, 31). The  present  data show that  the 370 
mutant enzyme is as  stable  to  heating  as  normal enzyme, but 
the 463 mutant enzyme is less thermostable.  These  data show 
that  the  apparent  inconsistencies of earlier  results  are prob- 
ably the consequence of true differences in  the  products of 
different  mutant genes. 
The results reported in this paper describe the different 
properties of six different  mutant glucocerebrosidase enzymes. 
I t  is apparent  that  one or more abnormalities may contribute 
to low enzymatic  activities  in  patient materials. Our  results 
confirm that  Gaucher disease is a  genetically  heterogeneous 
disorder caused by different  mutations producing gene prod- 
ucts  with  distinctly  different properties. Elucidation of the 
biology of the  disorders  resulting  from  the  mutations  acting 
either  alone  or  in  combination will require  considerably fur- 
ther  investigation  in  order  to  understand  the  relationship of 
genotype to  phenotype  in  this  group of disorders. 
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